Impact of statin therapy on late target lesion revascularization after sirolimus-eluting stent implantation (from the credo-kyoto registry cohort-2)
The American Journal of Cardiology, 05/01/2012
Natsuaki M et al. – Statin therapy at hospital discharge was associated with a significantly lower risk for late target lesion revascularization (TLR) after sirolimus–eluting stent (SES) implantation.Methods
- In 13,087 consecutive patients undergoing first percutaneous coronary intervention in the CREDO–Kyoto Registry Cohort–2, authors identified 10,221 patients who were discharged alive after implantation of sirolimus–eluting stents (SESs) only (SES stratum 5,029) or bare–metal stents (BMSs) only (BMS stratum 5,192).
- Impact of statin therapy at time of discharge from the index hospitalization on early (within the first year) and late (1 year to 4 years) TLR, was assessed in the SES stratum (statin group 2,735; nonstatin group 2,294) and in the BMS stratum (statin group 2,576; nonstatin group 2,616).
- Despite a significantly lower incidence of early TLR (7.8% vs 22.2%, p <0.0001), SES use compared to BMS use was associated with a significantly higher incidence of late TLR (7.7% vs 3.0%, p <0.0001).
- In the SES and BMS strata, the incidence of early TLR was similar regardless of statin use.
- In the SES stratum, the incidence of late TLR was significantly lower in the statin group than in the nonstatin group (6.1% vs 9.6%, p = 0.002), whereas no significant difference was found in the BMS stratum (2.6% vs 3.3%, p = 0.38).
- After adjusting confounders, risk for late TLR significantly favored statin use in the SES stratum (hazard ratio 0.73, 95% confidence interval 0.54 to 0.98, p = 0.04), whereas the risk decrease was not significant in the BMS stratum (hazard ratio 0.74, 95% confidence interval 0.46 to 1.20, p = 0.23).